Interferon alpha

This page contains recent news articles, when available, and an overview of Interferon alpha but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

News: Interferon alpha

Treatment rates for hepatitis C virus declining, say researchers  -  23 Nov 2009
News-Medical.netMichael Volk, MD, M.Sc., and colleagues obtained data of new patient prescriptions for pegylated interferon alpha-2a and -2b, sold under the brand names ...

Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical ...  -  ‎Nov 5, 2009‎
ReutersThe trial was designed to enroll 120 patients, whereby half were intended to receive Topical Interferon Alpha-2b and the other half a vehicle cream intended ...

Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug ...  -  ‎Nov 3, 2009‎
Reuters..."Induction of endogenous interferon-alpha and other antiviral proteins by IMO-2125 provides a novel immunotherapy approach to the potential treatment of ...

Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on ...  -  ‎Nov 6, 2009‎
CNNMoney.com (press release)Mr. Docherty will provide an overview of the Company's leading product development programs L-DOS47 and Topical Interferon Alpha-2b. ...

Research on depression risk factors reported by scientists at Ludwig ...  -  ‎Nov 16, 2009‎
Behavioral Health Central (blog)Current study results from the report, 'Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C,' ...

ZymoGenetics receives milestone payment  -  ‎Oct 28, 2009‎
FavStocks (blog)...a unique receptor that activates the same signaling pathway as Interferon Alpha, but with more restricted distribution compared to Interferon Alpha. ...

Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518 ...  -  ‎Nov 2, 2009‎
Reuters...of chronic hepatitis C in patients with compensated liver disease previously untreated with interferon alpha and who are at least 18 years of age. ...

Amarillo Biosciences Comments on New Findings of H1N1 in Animals and Potential ...  -  ‎Nov 11, 2009‎
CNNMoney.com (press release)Fortunately, oral or intranasal interferon alpha has been reported by scientists in France, Italy, Germany, Taiwan and the USA to be safe and beneficial in ...

Expansion plan invigorates Aurobindo Pharma  -  ‎Nov 22, 2009‎
India Infoline.com...the treatment for adults with chronic Hepatitis C Virus who have compensated liver disease and have not previously been treated with interferon alpha. ...

InterMune, Inc. Q3 2009 Earnings Call Transcript  -  ‎Nov 10, 2009‎
Seeking Alpha (blog)...in combination with pegylated interferon alpha 2A, ribavirin, and in combination with both pegylated interferon alpha 2A and ribavirin. ...

Helix BioPharma completes enrollment in Phase II ano-genital warts trial  -  ‎Nov 9, 2009‎
Trading Markets (press release)The trial was designed to enroll 120 patients, whereby half were intended to receive topical interferon alpha-2b and the other half a vehicle cream intended ...

Hepatitis C: A Public Health Problem  -  ‎Nov 5, 2009‎
North American Press SyndicateThe current standard of care is a combination of medicines called pegylated interferon alpha and ribavirin. Pegylated interferon alpha is given as a ...

SCYNEXIS` SCY-635 Demonstrates Positive Antiviral Activity in Combination with ...  -  ‎Nov 3, 2009‎
ReutersAccording to the study, SCY-635 demonstrated additive to synergistic activity when combined with interferon alpha and ribavirin, the current standards of ...

Helix BioPharma Corp. Announces Fiscal 2009 Results  -  ‎Oct 29, 2009‎
ReutersEnrollment in the ongoing Phase II clinical trial of Topical Interferon Alpha-2b in patients with anogenital warts ("AGW") in Sweden and Germany is ...

Retinoic acid inducible gene I activates innate antiviral response against ...  -  ‎Nov 17, 2009‎
7thSpace Interactive (press release)Type-I interferons (IFN, interferon-alpha/beta) and tumor necrosis factor-alpha (TNF activated by NF-kappa B) are potent antiviral cytokines that play an ...

OTC Stock Review: OTC Stock Review Stocks in Motion for Thursday, November 19 ...  -  ‎Nov 19, 2009‎
Trading Markets (press release)...revenue in the next 1-2 years from the marketing and selling of two pharmaceutical products called ribavirin and pegylated-interferon-alpha-2b products. ...

Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518 ...  -  ‎Nov 4, 2009‎
CNNMoney.com (press release)...of chronic hepatitis C in patients with compensated liver disease previously untreated with interferon alpha and who are at least 18 years of age. ...

Biovitrum Will Pay up to $533M for Swedish Orphan  -  ‎Nov 10, 2009‎
BioWorld OnlineMultiferon (interferon), which comprises six interferon-alpha subtypes, is approved in 15 European Union states for treating advanced malignant melanoma and ...

Biovitrum to buy Swedish Orphan in $494 million deal  -  ‎Nov 5, 2009‎
Pharma TimesThese are Orfadin (nitisinone), the only available pharmaceutical for hereditary tyrosinemia type 1 and Multiferon, a human multi-subtype interferon alpha ...

Refocusing on Therapeutic Protein Production in Plants  -  ‎Nov 20, 2009‎
Genetic Engineering News (press release)Biolex' lead product, Locteron, combines BLX-883, a recombinant interferon alpha produced in the LEX system, with controlled-release drug-delivery ...

REG-Biocompatibles Intl.: Statement re Positive Data in Combination Therapy Trial  -  ‎Nov 3, 2009‎
ReutersTreatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable ...

HCV Vaccines, TLRs Advance Away from Protease Spotlight  -  ‎Nov 4, 2009‎
Therapeutics Daily (press release) (registration)At AASLD, Idera presented preclinical data showing that IMO-2125 induced the production of cytokines and chemokines, including endogenous interferon-alpha, ...

Vertex Hepatitis C Drug Passes Key Test With More Convenient, Twice-Daily Dose  -  ‎Oct 31, 2009‎
XconomyThe drug is currently being tested as an oral pill that patients take in combination with the standard treatments—pegylated interferon alpha and ribavirin. ...

SCYNEXIS to Present HCV Data on Novel Cyclophilin Inhibitor SCY-635 at AASLD ...  -  ‎Oct 28, 2009‎
Reuters...non-nucleoside polymerase inhibitors, nucleoside polymerase inhibitors, protease inhibitors (boceprevir, telaprevir), ribavirin and interferon alpha 2b. ...

Gene-Environment Interactions and Depression  -  ‎Nov 3, 2009‎
Journal of American Medical Association (subscription)Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry. 2009;65(4):344-348. ...

Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG ...  -  ‎Oct 31, 2009‎
Reuters...that binds to a unique receptor with more restricted distribution than the receptors targeted by type 1 interferons, such as interferon alpha. ...

US nod for generic drug boosts Aurobindo Pharma  -  ‎Nov 5, 2009‎
India Infoline.com...the treatment for adults with chronic Hepatitis C Virus who have compensated liver disease and have not previously been treated with interferon alpha. ...

Clinic Roundup  -  ‎Nov 6, 2009‎
Therapeutics Daily (press release) (registration)Helix BioPharma Corp., of Aurora, Ontario, completed patient enrollment in its 120-subject Phase II trial of topical interferon alpha-2b in ano-genital ...

OctoPlus Publishes Third Quarter Business Update  -  ‎Nov 14, 2009‎
PR-USA.net (press release)...release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. ...

www.StockMarketingInc.com: Wow!! Don't Miss Out!!! AYRC,WEMU,CPBM,BLFS,ENTB,LFBG  -  ‎Nov 18, 2009‎
Trading Markets (press release)...revenue in the next 1-2 years from the marketing and selling of two pharmaceutical products called ribavirin and pegylated-interferon-alpha-2b products. ...

OctoPlus Publishes Third Quarter Business Update  -  ‎Nov 8, 2009‎
Market Wire (press release)...release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. ...

Helix BioPharma Corp. schliesst Aufnahme von Patienten mit anogenitalen Warzen ...  -  ‎Nov 6, 2009‎
PresseEcho.de (Pressemitteilung)Patientin in die Phase-II-Studie zur Behandlung von anogenitale Warzen (AGW) mit Topical Interferon Alpha-2b des Unternehmens die Patientenrekrutierung in ...

Médicaments: Les princeps surprotégés  -  ‎Nov 5, 2009‎
L'ÉconomisteLe cas d'Interferon alpha 2a-pégylé prescrit pour l'hépatite C est éloquent à cet égard. Ce médicament représente le poste de dépense le plus important dans ...

Helix BioPharma Corp. gibt Ergebnisse des Geschäftsjahres 2009 bekannt  -  ‎Nov 3, 2009‎
PresseEcho.de (Pressemitteilung)Topical Interferon Alpha-2b - Ein vorbereitendes IND-Gespräch wurde mit der FDA geführt, in der die FDA eine randomisierte vehikelkontrollierte klinische ...



Background information on Interferon alpha [When available]

Biological therapy is a type of treatment that works with your immune system. It can help fight cancer or help control side effects (how your body reacts to the drugs you are taking) from other cancer treatments like chemotherapy.

What is the difference between biological therapy and chemotherapy?

Biological therapy and chemotherapy are both treatments that fight cancer. While they may seem alike, they work in different ways. Biological therapy helps your immune system fight cancer. Chemotherapy attacks the cancer cells directly.

How does biological therapy fight cancer?

Doctors are not sure how biological therapy helps your immune system fight cancer. But they think it may:
  • Stop or slow the growth of cancer cells.
  • Make it easier for your immune system to destroy, or get rid of, cancer cells.
  • Keep cancer from spreading to other parts of your body.
More from the National Cancer Institute

Search the web for more resources on Interferon alpha



Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy